Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NK Cell Therapy for the Treatment of Malignant Solid Brain Tumors

NCT07552233 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07552233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NK Cell Therapy for the Treatment of Malignant Solid Brain Tumors
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
April 30, 2026
Completion date
December 31, 2030
Enrollment
27 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastasis, glioblastoma (gbm), glioblastoma multiforme (gbm), malignant meningioma, malignant solid brain tumors